Kornimate/medical-research-clean huggingface dataset:
sleep and memory in children

Conditions: Sleep Apnea; Temporo-central Epilepsy; Narcolepsy; High Intellectual Potential; Healthy Subject

Summary: sleep exerts a dual effect on learning: on the one hand, good sleep quality allows good daytime aptitudes leading to knowledge acquisition. on the other hand, sleep after learning is necessary for knowledge consolidation. a key role of sleep has clearly been demonstrated in memory consolidation in adults. sleep leads to strengthen memory by promoting brain plasticity. surprisingly, sleep influence on learning stabilization has scarcely been studied during childhood and in children affected by sleep disorders. yet, sleep disorders concern almost 30% of children and are frequently related to a worsening in academic performances. classical neuropsychological evaluations of these children, based on daytime learning, often fail to determine cognitive profiles explaining their academic difficulties. the investigators hypothesize that a lack of sleep-dependent consolidation could take an active part in these children's cognitive and academic difficulties. this proposal aims at characterizing interactions between sleep, learning and memory processes that have not been studied in children of elementary school age (6-12 years). the investigators will evaluate sleep-dependent memory consolidation processes in children with sleep disorders before and after treatment and healthy controls. neuropsychological testing and academic performances will be also evaluated.. the comparison of performances obtained before and after medical treatment, will allow to understand whether normalisation of sleep quality permits the restoration of sleep-dependent memory consolidation.


Eligibility criteria:
inclusion criteria: * aged between 6 and 12 y * referred to the hfme for a suspicion of sleep apnea * narcolepsy * centro-temporal epilepsy * high intellectual potential * children without sleep disorders will be included in the healthy control group.

Keywords: memory sleep narcolepsy apnea epilepsy
multimodal dvt protocol in tourniquet-less total knee arthroplasty

Conditions: Deep Vein Thrombosis

Summary: the cothera vpulse(tm) mechanical compression device (mcd) combines rapid intermittent sequential compression with cold therapy and is designed for single patient use in the home. additionally, it can track patient compliance. this study will examine if there is a difference in deep vein thrombosis (dvt) occurrence over 3 weeks after tourniquet-less total knee arthroplasty (tka) and multimodal prophylaxis with or without extended mcd use in a cooling device/mcd system.

in recent years there has been significant progress towards more effective and practical thromboprophylaxis in joint replacement surgeries. since aspirin 325mg twice daily has been recently included as a nationally approved venous thromboembolism (vte) prophylaxis in the surgical care improvement project (scip) protocols for low risk total knee arthroplasty (tka) patients, it is necessary to optimize multimodal prophylaxis methods. these include reduced tourniquet time, early mobilization, and mechanical compression devices (mcds). mcds are commonly used as part of the in-hospital vte prophylaxis measures; however, it has not been demonstrated in clinical trials that optimal prophylaxis methods would be enhanced by prolonged use of a mcd after discharge. in order to achieve this, a potentially valuable solution has recently been made available to the outpatient population. the cothera vpulse(tm) is a mcd that combines rapid intermittent sequential compression with cold therapy. it is designed for single patient use in the home and includes technology to track patient compliance. the purpose of this study is to examine if there is a difference in dvt occurrence over 3 weeks after tourniquet-less tka and multimodal prophylaxis with or without extended mcd use in a cooling device/mcd system.

Eligibility criteria:
inclusion criteria: * tka candidacy, osteoarthritis, patients able to understand study intent, and agree to study participation exclusion criteria: * subjects with personal or family history of dvt, currently taking antiplatelet/anticoagulant drugs, genetic risk factor positive for vte, pronounced thrombocytopenia, gi bleed within 6 months of surgery, nsaid intolerance, orthopaedic and medical co-morbidities that would prevent postoperative rapid mobilization and compliance with mcd such as extra-articular pathology with referred pain to the knee (spinal stenosis, neuropathy, ipsilateral hip disease), severe knee deformity, post-traumatic and inflammatory arthritis, bmi above 40, active knee sepsis, remote sites of active infection, asa class \> lll, cardiac disease failing medical clearance, severe liver disease, peripheral artery disease, seizure disorder, alcohol abuse, smoking abuse

Keywords: dvt total knee arthroplasty
the effects of premeal consumption of protein-enriched bar on blood glucose level and secretion of hormones

Conditions: Diabetes Mellitus

Summary: the aim of this study is to explore premeal protein-enriched bar effect in postprandial glucose levels and concentration of plasma incretin hormones \[glucagon-like peptide 1 (glp-1) and/or glucose-dependent insulinotropic polypeptide (gip)\] in healthy subjects and those with type 2 diabetes.

fifteen healthy subjects and fifteen subjects with type 2 diabetes treated by diet and/or metformin, su, dpp4 inhibitors will be recruited. every subject will studied on 2 separate days in random order with 1-2 week intervals. these participants will consume protein enriched bar followed by a standardized high-glycemic-index breakfast in a hospital setting or breakfast followed protein enriched bar in a cross-over fashion. blood sampling will be done at the moment of start of breakfast (0 min) and then 10, 20, 30, 60, 90, 120, 150, 180 min. plasma glucose levels, total/active glp-1, gip, insulin, c-peptide, glucagon will be measured. incremental area under the curve (iauc) of glucose level and hormone from 0 min to 180 min will be calculated.

Eligibility criteria:
inclusion criteria: * bmi 18.5\~35 kg/m2 * healthy volunteer: * never diagnosed by diabetes and * fasting plasma glucose \<=100mg/dl and hba1c \<6.0% * participants with diabetes * diagnosed by diabetes * if treated by diet, hba1c 6.0\~9.0% * if treated by metformin or su, hba1c 6.0\~10.0% * if treated by dpp4 inhibitor hba1c 6.0\~9.0% exclusion criteria: * those who diagnosed by type 1 diabetes * history of dka * history of insulin therapy * allergy to wheat, flour, nuts, milk * pregnancy/lactation * ast or alt \>2.5 times of upper normal reference range * egfr \<30 ml/min/1.73m2 * hb \<10g/dl * history of gi surgery (except hemorrhoidectomy, appendectomy)

Keywords: diabetes mellitus incretin hormone glucose level glp-1 gip premeal protein
oxycodone user registry (our)

Conditions: Pain

Summary: the purpose of this study is to describe clinical and demographic characteristics of patients receiving prescription medications containing oxycodone immediate release (oxyrx), to characterize patient and prescriber perceptions of the effectiveness outcomes and tolerability of oxyrx treatment, to describe prescriber decision-making about pain management with a schedule ii opioid and to explore how prescribers identify suspected abuse of pain medications.

real-world utility of schedule ii immediate release opioids depends on both efficacy and side effects. few existing data sources systematically captured opioid-related side effects and their impact on patient outcomes and physician practice. this study is expected to lead to an in-depth understanding of patient and prescriber perceptions of both effectiveness and side effects associated with medications containing the most widely prescribed oral schedule ii immediate release opioid for pain management, oxycodone immediate release (oxyrx), alone (eg, roxicodone®) or in combination (eg, percocet®, tylox®) in actual clinical practice. this is a prospective, multi-center, observational patient registry. adult outpatients who have pain due to a non-cancerous condition meeting study eligibility will be enrolled. prescribers will treat patients according to their usual practice. prescribers will treat patients, meeting study eligibility, with oxyrx according to their usual practice.

Eligibility criteria:
inclusion criteria: * pain requiring treatment with a schedule ii immediate release opioid within 3 days following the baseline visit * and pain that warrants treatment with a prescription for oxyrx prn (alone or in combination) for at least 5 days after the baseline visit exclusion criteria: * use of any schedule ii opioid within 30 days prior to informed consent * planned use of other opioids (schedule ii-v) while using oxyrx * malignancy other than superficial skin cancers (ie, basal cell, squamous cell) within the past year

Keywords: pain conditions oxycodone immediate release percocet®, tylox® roxicodone® registry side effects observational pain management
a study of combination therapy with pegasys (pegylated interferon alfa-2a (40kd)) and copegus (ribavirin) in patients with chronic hepatitis c genotype 2 or 3 who do not achieve a rapid viral response

Conditions: Hepatitis C, Chronic

Summary: this study will evaluate the efficacy and safety of peginterferon alfa-2a 40kd + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis c, genotype 2/3.

during a pre-study run-in phase patients with chronic hepatitis c genotype 2/3, who had started therapy with peg-ifn alfa-2a plus ribavirin according to local standard of care and did not achieve a rapid viral response (rvr) (defined as hepatitis c virus (hcv) rna \<15 iu/ml at week 4 of treatment measured with the roche cobas ampliprep / cobas taqman® hcv test) were eligible for the study and entered the screening phase between treatment week 4 and 8 as soon as the result of the week 4 hcv rna test was available. eligible patients entered the study and continued with the dose regimens of peg-ifn alfa-2a and ribavirin they were taking prior to enrolment into the trial up to week 24 of treatment. patients who achieved at least a 2-log10 drop of hcv rna at week 12 (as compared to hcv rna levels prior to treatment initiation) or had hcv rna \<15 iu/ml, and who were still taking study medication at treatment week 24, were randomized at treatment week 24 to one of the two study groups. upon randomization, participants either stopped treatment (equaling 24 weeks of treatment) or continued treatment for another 24 weeks (equaling 48 weeks of treatment). a treatment free follow-up period of 24 weeks (for participants in the 48-week treatment group) or 48 weeks (participants in the 24-week treatment group) completed the study.

Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * serological evidence of chronic hepatitis c (chc); * chc genotype 2 or 3; * receiving pegasys + copegus according to local standard of care and no rapid viral response (rvr); * compensated liver disease. exclusion criteria: * pegylated interferon, standard interferon or ribavirin therapy at any time prior to initiation of current therapy with pegasys + copegus; * coinfection with hepatitis a or b, or human immunodeficiency virus (hiv); * history or other evidence of decompensated liver disease.
the effect of erector spina plan block application time on postoperative anxiety

Conditions: Recovery of Postoperative

Summary: we aimed to compare the effect of preoperative awake or post-induction erector spina plane block on patient anxiety and recovery quality in patients who will undergo elective lumbar disc hernioplasty.

postoperative recovery quality can be tested with the quality of recovery-40 (qor-40) questionnaire. preoperative anxiety can be detected through structured and standardized screening with the state-trait anxiety inventory (stai) i and ii. in our study, 108 patients between the ages of 18-70 who were planned for lumbar disc hernioplasty will be included. preoperative quality of recovery-40 (qor40), stai i and ii scores (anxiety questionnaire) will be administered to each patient.the patients will be divided into two groups as preoperative ve intraoperative group. erector spina plane block will be applied to preoperative group patients in the preoperative period. in the intraoperative group, erector spina plane block will be applied after anesthesia induction. the stai and quality of recovery-40 (qor40) questionnaire will be repeated postoperatively, the numerical rating scale (nrs) and postoperative patient satisfaction will be measured.

Eligibility criteria:
inclusion criteria: * 18-70 years old * american society of anesthesiologists score i-ii-iii * patients who can read and write * can speak turkish language clearly exclusion criteria: * visual and hearing impaired * those with dementia * known serious heart, kidney and liver diseases * life-threatening hematological diseases * central and peripheral neurological diseases * psychiatric disorders * history of allergy to amide type local anesthetics * infection in the block area * bleeding diathesis * morbidly obese (patients with bmi 40 and above) * a history of narcotic drug use within 24 hours before the operation * those with narcotic substance and alcohol addiction related to chronic pain * patients who refused to participate in the study

Keywords: block timing quality of recovery erector spina plan block
local methotrexate injections for the treatment of nail psoriasis

Conditions: Nail Psoriasis

Summary: the investigators hope to learn the efficacy of methotrexate injections for treatment of nail psoriasis.


Eligibility criteria:
inclusion criteria: * subject must be at least 18 years of age * subject must have nail psoriasis that is clinically diagnosed in at least 3 fingernails exclusion criteria: * subject with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study. this is including, but not limited to: immunodeficiency, onychomycosis, any other nail condition other than psoriasis, allergy to methotrexate, triamcinolone acetonide, local anesthetic, normal saline, or any other material used for procedures * subject who has received radiation therapy, chemotherapy, and/or immunosuppressive drugs within 6 months of study, and/or oral corticosteroids or iv methotrexate for \>1 month within the 6 months of study (exception inhaled steroids); * subjects who use substances (medications, supplements, ect) known to significantly interact with drugs used as intervention in the study * subject who is pregnant, breastfeeding, or planning to get pregnant * subject known to have received treatment with investigational drugs or devices within 30 days prior to enrollment into this study * subject who is on systemic treatment for psoriasis * subject with baseline abnormalities in liver function tests or complete blood count * subjects with diagnosis of renal insufficiency or impairment * subject who is unwilling to abstain from any cosmetic nail treatments outside those provided by the study clinic, beyond basic nail trimming (i.e. no spa nail treatments, no nail polish use, no other topical prescription nail medication) * subject who is unwilling to abstain from any medical nail treatments on their nails other than the study intervention (i.e. topical steroids, antifungal creams) for the duration of the study intervention and for duration of the washout period (if applicable) * subject who is part of the staff personnel directly involved with this study or a family member of the investigational study staff

Keywords: methotrexate triamcinolone acetonide
effectiveness of a school-centered prevention program on prevalence of latent rheumatic heart disease

Conditions: Rheumatic Heart Disease; Rheumatic Heart Disease in Children

Summary: the overall objective is to evaluate the effectiveness of a school-centered primary and secondary prevention program on the prevalence of latent rheumatic heart disease among schoolchildren in nepal, and to investigate the role of socioeconomic and environmental factors in the development and progression of rheumatic heart disease.

three in four children worldwide grow up in regions of the world where patterns of acute rheumatic fever and rheumatic heart disease are endemic and where rheumatic heart disease accounts for \>300'000 deaths every year. evidence from a systematic review and meta-analysis of 10 studies indicated an incidence of group a β-hemolytic streptococcal (gahbs) pharyngitis among children in low- to upper-middle income countries of 10.8 per 100 child-years with considerable heterogeneity between individual reports. timely detection of gahbs pharyngitis by use of rapid antigen detection tests and initiation of antibiotic treatment represents an effective target for primary prevention. early stages of rheumatic heart disease manifest with morphologic or functional valvular changes that can only be detected with echocardiography and are therefore latent. latent stages of rheumatic heart disease are reversible with timely initiation of secondary antibiotic prophylaxis. a school-centered approach provides an opportunity to provide equitable access to a primary and secondary prophylaxis program with the potential to substantially reduce the burden of rheumatic heart disease in endemic regions. all children 5-16 years of age from tulsi secondary boarding school in tulsipur, nepal, will be eligible for inclusion. sociodemographic characteristics and will be collected by means of a standardized interview. in a study using an interrupted time series design, prevalence of latent rheumatic heart disease will be measured by means of transthoracic echocardiography before, and two and four years after implementation of a dedicated school nurse program providing health care through assessment, intervention and follow-up of gahbs pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease. investigators expect to find a decrease in prevalence of rheumatic heart disease after implementation of a dedicated school-centered prevention program primarily led by school nurses, and to identify sociodemographic and environmental factors associated with the development and progression of rheumatic heart disease.

Eligibility criteria:
inclusion criteria: * age 5-16 years * attending tulsi secondary boarding school in tulsipur, nepal. exclusion criteria: * children / primary caregivers not providing informed consent to participate * children not attending tulsi secondary boarding school in tulsipur.

Keywords: rheumatic heart disease primary prevention secondary prevention screening
impact of covid-19 on personal protection among dentist in egypt

Conditions: COVID 19

Summary: dentist exposed to coronavirus (covid-19) may not have adequate access to personal protective equipment (ppe), safety procedures, and diagnostic protocols. our objective will be to evaluate the reality and perceptions about personal safety among dentist in egypt

this is a cross-sectional, online survey-based study administered to dentist in egypt. a 20-item questionnaire will be developed and distributed using google forms. participants were recruited through social networking websites and applications (twitter, instagram, facebook, linkedin, and whatsapp). the questionnaire will be conducted from 24 may 2020 and until 30 june 2020. the survey will be delivered in enlish. participants will be able to complete the survey only once and will be allowed to terminate the survey at any time they desired. the survey will be anonymous and confidential. an introductory paragraph outlining the purpose of the study will be posted along with the survey.

Eligibility criteria:
inclusion criteria: all dentist actively working in egypt exclusion criteria: * non dentist * resident outside egypt

Keywords: covid-19 personal protection dentist egypt
inheritance of osteosarcoma & paget's disease through chromosome 18:

Conditions: Osteosarcoma; Paget's Disease

Summary: researchers have previously demonstrated loss of heterozygosity in a region on chromosome 18q, associated with osteogenic sarcomas in bone affected by paget's disease. the loci used in this study are specifically described by those authors as showing loss of heterozygosity in 6 of 7 affected families.

as above, no additional information

Eligibility criteria:
inclusion criteria: * this is a familial study therefore the only inclusion/exclusion criteria would be that subjects must be a blood relative and over the age of 18. * the subjects are proband and father along with unaffected blood relatives. their peripheral blood will act as a control and provide information to delineate the inheritance from the father, as seen in the son. exclusion criteria: * not part of the family

Keywords: inheritance of osteosarcoma & paget's disease through chromosome 18
phase 1b, open-label study to evaluate the safety, tolerability, and pharmacodynamics of ep262 in subjects with chronic inducible urticaria

Conditions: Chronic Inducible Urticaria

Summary: this phase 1b trial will evaluate the effects of ep262 in subjects with chronic inducible urticaria (cindu), including symptomatic dermographism and cold urticaria.


Eligibility criteria:
inclusion criteria: * diagnosis of cindu (symptomatic dermographism or cold urticaria) for greater than 3 months and positive response to applicable skin provocation testing * willing to discontinue chronic treatment with antihistamines during the study exclusion criteria: * urticaria with a clear underlying etiology other than symptomatic dermographism or cold urticaria * other active skin diseases that might confound the study evaluations (eg, atopic dermatitis, bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis) * regularly experience wheals covering the area of the body where skin testing will be conducted (eg, more than one third of the volar surface of the forearms)
vitamin b12 pregnancy supplementation

Conditions: Pregnancy Anemia

Summary: pregnancy is associated with increased requirements for iron and increased blood volume of up to 40%. because expansion in plasma volume is higher than the increase in the mass of red blood cells, there is a fall in hemoglobin concentration, which leads to physiological anemia, characterized with lower hemoglobin (hb), hematocrit and red blood cells, but without changes in mean corpuscular volume (mcv). anemia in pregnancy is defined with hb values under 110 g/l in the first trimester and under 105 g/l in the second and third trimester. iron deficiency is thought to be the most common nutrient deficiency among pregnant women. consequences of anemia include delayed fetal growth, premature delivery, intrauterine fetal death, postpartum depression and delayed psychomotor development of a child. it is known that in women that are not anemic daily iron supplementation of 27 mg/day is sufficient, which can be obtained from adequate nutrition or body supplies. iron supplementation is pregnancy has been recommended by the who (world health organisation) since 1959, and this recommendation was confirmed by numerous professional associations. however, in women with anemia, or women subjected to particular dietary regimens with diminished quantity of iron, including vegetarian or vegan diet, required supplementation dosage is higher, and estimated in the literature to be 120 mg/day. the aim of this study was to analyze whether adding vitamin b12 (5 µg /100 days), along with folic acid and iron as supplement in pregnant women who are not anemic and who need only iron supplementation, will result in improvements of hematological and biochemical markers.


Eligibility criteria:
inclusion criteria: * healthy women from 8th week of pregnancy exclusion criteria: * existence of hypertension * existence of diabetes * existence of genetic abnormalities * smoking * previous miscarriage

Keywords: vitamin b12 pregnancy anemia